Actinium Pharmaceuticals (ATNM) Q3 2024 earnings summary

Executive summary

• Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing Antibody Radiation Conjugates (ARCs) and targeted radiotherapies for cancer, with lead candidates Iomab-B, Actimab-A, and Iomab-ACT in various stages of clinical development.

• The company is seeking to address high unmet needs in hematology and oncology, particularly for relapsed or refractory acute myeloid leukemia (AML) and conditioning for bone marrow transplant (BMT) and cell/gene therapies.

• Iomab-B's pivotal Phase 3 SIERRA trial met its primary endpoint, but the FDA requires an additional head-to-head Phase 3 trial and a dose optimization study before a Biologics License Application (BLA) can be filed.

• Actimab-A is advancing in combination studies for AML, supported by a CRADA with the National Cancer Institute (NCI), and is included in the myeloMATCH program for precision medicine trials.

• The company is actively seeking a strategic partner for Iomab-B in the U.S. and continues to expand its pipeline and preclinical programs.

Financial highlights

• No commercial or other revenue was recognized for the three and nine months ended September 30, 2024 and 2023.

• Research and development expenses for Q3 2024 were $9.8 million, down from $11.6 million in Q3 2023; for the nine months ended September 30, 2024, R&D expenses were $25.2 million, down from $30.6 million in the prior year period.

• General and administrative expenses for Q3 2024 were $2.8 million, up slightly from $2.7 million in Q3 2023; for the nine months ended September 30, 2024, G&A expenses were $9.4 million, down from $11.0 million in 2023.

• Net loss for Q3 2024 was $11.6 million, an improvement from $13.3 million in Q3 2023; net loss for the nine months ended September 30, 2024 was $31.6 million, improved from $39.5 million in the prior year period.

• Cash, cash equivalents, and restricted cash totaled $79.0 million as of September 30, 2024, with net cash used in operating activities of $27.3 million for the nine months ended September 30, 2024.

Outlook and guidance

• Management expects existing resources to fund planned operations for more than 12 months from the date of the report.

• The company is focused on advancing additional clinical trials for Iomab-B as required by the FDA and progressing Actimab-A in combination studies under the NCI CRADA.

• Strategic partnerships are being sought to support further development and commercialization, particularly for Iomab-B in the U.S.